domain

Pioglitazone (U 72107) is a PPARγ agonist with EC50 of 0.93 and 0.99 μM on human and mouse PPARγ, respectively, and has selective and oral activity. Pioglitazone can be used in diabetes research.

Apoptozole (Apoptosis Activator VII) inhibits the ATPase domain of Hsc70 and Hsp70, inducing apoptosis.

Tetramethylcurcumin is a novel curcumin analog, is an effective inhibitors of STAT3 phosphorylation, DNA binding activity, and transactivation in vitro.it also inhibits colony formation in soft agar, cell invasion, and exhibit synergy with the anti-cancer drug doxorubicin against breast cancer cells.

Bioymifi (DR5 Activator) is an effective activator of the TRAIL receptor DR5, binding to the extracellular domain (ECD) of DR5 with a Kd of 1.2 μM. Bioymifi can serve as a novel mimetic of TNF-related apoptosis-induced ligand (TRAIL), inducing DR5 aggregation as a sole inducer, and stimulating cell apoptosis.

ML324(IC50=920 nM) is a specific inhibitor of jumonji histone demethylase (JMJD2).

EPI-001 is an androgen receptor N-terminal domain antagonist with IC50 of ～6 μM and a selective PPAR-gamma modulator.

MR837 (NSD2-PWWP1 antagonist 3f) is a NSD2-PWWP1 antagonist.

Clathrin-IN-1 is a inhibitor of clathrin, and inhibits clathrin-mediated endocytosis (CME) by associating with the terminal domain of clathrin. It has the potential for anti-cancer research.

SSAA09E2 is a new SARS-CoV replication inhibitor, acting by blocking early interactions of SARS-S with the receptor for SARS-CoV, Angiotensin Converting Enzyme-2 (ACE2).

Stafia-1 is a potent STAT5a inhibitor (IC50=22.2 μM), displaying high selectivity over STAT5b and other STAT family members.

The Anti-Spike-RBD Single Domain mAb is a monoclonal antibody derived from CHO cells in Alpaca. It is composed of VHH-huFc and exhibits a strong affinity for the SARS-CoV-2 RBD. [1]

Tau Peptide (275-305), also known as the R2 domain fragment, represents the second repeat unit of the microtubule-binding domain of the Alzheimer's tau peptide. Tau Peptide (275-305) is considered crucial in determining the biochemical characteristics of the complete tau protein.

PDZ1 Domain Inhibitor Peptide TFA, a cyclic peptide featuring a β-Ala lactam side chain linker, specifically targets the PDZ1 domains of postsynaptic density protein 95 (PSD-95). It effectively disrupts the GluR6/PSD-95 interaction, competing against the C terminus of GluR6 for the PDZ1 domain with high efficiency [1].

Grb2 SH2 Domain Inhibitor 1 TFA is a cyclic cell-penetrating peptide (CPP) featuring a conformationally restricted d-pro-l-pro motif ring (AF Φ Rpprrfq), where Φ represents L-naphthylalanine, R signifies D-arginine, and P stands for D-proline. It primarily functions as a cyclic peptide inhibitor.

Grb2 SH2 Domain Inhibitor 1 is a cyclic cell-penetrating peptide (CPP) featuring a conformationally restricted d-pro-l-pro motif ring (AF Φ Rpprrfq), where Φ represents L-naphthylalanine, R denotes D-arginine, and P indicates D-proline. This compound primarily functions as a cyclic peptide inhibitor.

SEB Domain (144-153) peptide is Staphylococcal Enterotoxin B domain amino acid residue 163-172. SEB Domain (144-153) has been shown to inhibit transcytosis of multiple staphylococcal enterotoxins, SEA, SEE, and TSST-1.

SEB Domain 144-153 acetate(210229-94-0 free base) is amino acid residues 163-172 of the staphylococcal enterotoxin B domain. SEB Domain 144-153 acetate(210229-94-0 free base) has been shown to inhibit the transcytosis of several staphylococcal enterotoxins, SEA, SEE, and TSST-1.

SEB Domain 144-153 TFA is Staphylococcal Enterotoxin B domain amino acid residue 144-153. It inhibits transcytosis of multiple staphylococcal enterotoxins, SEE, SEA, and TSST-1.

Novel cyclic peptide that disrupts interaction between GluR6 and PSD-95

SEB Domain (152-161) TFA represents amino acid positions 152-161 within the structural domain of staphylococcal enterotoxin B, produced by Staphylococcus aureus. This segment is highly conserved and inhibits the transcytosis of multiple staphylococcal enterotoxins, including SEA, SEE, and TSST-1.

HexokinaseIIVDACbinding domain peptide (Hxk2VBD peptide) is a cell-permeable peptide derived from the hexokinase II VDAC binding domain. This peptide inhibits the mitochondrial localization of hexokinase 2 (HXK2) and also suppresses neurotrophic factor-induced axon growth.

ApolipoproteinKV domain (67-77) is an 11-amino-acid peptide isolated from the KV domain of human apolipoprotein a (ApoA), known for its anti-angiogenic and anti-tumor activities. It targets the angiogenesis c-Src/ERK pathway by blocking activation signals received from vascular endothelial growth factor (VEGF). ApolipoproteinKV domain (67-77) is applicable in cancer research.

Bromodomain Inhibitor-13 (Compound 1), an analog of PFI-3, is a bromodomain-containing protein (BCP) inhibitor. It specifically targets the bromodomains of SMARCA2, SMARCA4, and the first and second bromodomains of PB1 [PB1(5) and PB1(2)], with dissociation constants (KD) of 37, 53, 30, and 190 nM, respectively.

BET bromodomain inhibitor is a potent BET inhibitor.